Intra-Cellular Therapies: Q4 Earnings Insights

 

Intra-Cellular Therapies ITCI reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Earnings

Intra-Cellular Therapies missed estimated earnings by 5.0%, reporting an EPS of $-1.05 versus an estimate of $-1.0.

Revenue was up $13.22 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.03 which was followed by a 2.93% drop in the share price the next day.

Here's a look at Intra-Cellular Therapies's past performance:

 

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate -0.92 -0.80 -0.80 -0.85
EPS Actual -0.95 -0.85 -0.65 -0.76
Revenue Estimate 22.12M 19.44M 16.50M 11.84M
Revenue Actual 22.21M 20.05M 15.88M 12.45M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!